Tjuana Durden Seidl
Medical · Lexington, SCNPI 1912378290
Payments from drug & device makers
Across 110 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$335
- Lilly USA, LLC$242
- Novo Nordisk$215
- Neurocrine Biosciences, Inc.$161
- Boehringer Ingelheim$99
- AstraZeneca$94
- plus $540 from 13 others
What the payments were for
- Food & beverage$1,687100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $335 |
| Lilly USA, LLC | 15 | $242 |
| Novo Nordisk | 13 | $215 |
| Neurocrine Biosciences, Inc. | 11 | $161 |
| Boehringer Ingelheim | 6 | $99 |
| AstraZeneca | 6 | $94 |
| Bayer | 5 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $84 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Abbott | 3 | $61 |
| GSK | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Esperion Therapeutics, Inc. | 1 | $31 |
| Pfizer | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Exact Sciences | 1 | $17 |
How this compares
$1,687 in reported general payments places this provider in the 60th percentile of 384 medical providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $64,336 |
| MounjaroTirzepatide | 42 | $50,374 |
| JanuviaSitagliptin Phosphate | 35 | $33,558 |
| TrulicityDulaglutide | 21 | $22,157 |
| JardianceEmpagliflozin | 17 | $16,350 |
| EliquisApixaban | 27 | $16,075 |
| FarxigaDapagliflozin Propanediol | 22 | $14,918 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,076 |
| LinzessLinaclotide | 20 | $10,599 |
| MyrbetriqMirabegron | 12 | $5,873 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,954 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,530 |
| Omeprazole | 165 | $3,022 |
| Enoxaparin Sodium | 12 | $2,929 |
| Aripiprazole | 12 | $2,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $242 | $72,53163 claims |
| Novo NordiskOzempic | $215 | $64,33668 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $94 | $27,99442 claims |
| Boehringer IngelheimJardiance | $99 | $16,35017 claims |
| PfizerEliquis | $20 | $16,07527 claims |
| AbbVieLinzess | $335 | $10,59920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 384 medical providers in South Carolina.
Other medical in Lexington
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.